Department of Chemistry, Indian Institute of Technology Bombay, Powai, Mumbai, Maharashtra 400076, India.
School of Mechanical Sciences, Indian Institute of Technology Goa, Farmagudi, Ponda, Goa 403401, India.
ACS Chem Biol. 2024 Oct 18;19(10):2165-2175. doi: 10.1021/acschembio.4c00336. Epub 2024 Sep 20.
Deciphering the functional relevance of every protein is crucial to developing a better (patho)physiological understanding of human biology. The discovery and use of quality chemical probes propel exciting developments for developing drugs in therapeutic areas with unmet clinical needs. Myosin light-chain kinase (MLCK) serves as a possible therapeutic target in a plethora of diseases, including inflammatory diseases, cancer, etc. Recent years have seen a substantial increase in interest in exploring MLCK biology. However, there is only one widely used MLCK modulator, namely, ML-7, that too with a narrow working concentration window and high toxicity profile leading to limited insights. Herein, we report the identification of a potent and highly selective chemical probe, Myokinasib-II, from the synthesis and structure-activity relationship studies of a focused indotropane-based compound collection. Notably, it is structurally distinct from ML-7 and hence meets the need for an alternative inhibitor to study MLCK biology as per the recommended best practices. Moreover, our extensive benchmarking studies demonstrate that Myokinasib-II displays better potency, better selectivity profile, and no nonspecific interference in relevant assays as compared to other known MLCK inhibitors.
阐明每个蛋白质的功能相关性对于发展对人类生物学的更好(病理)生理学理解至关重要。优质化学探针的发现和使用推动了在具有未满足临床需求的治疗领域开发药物的令人兴奋的发展。肌球蛋白轻链激酶(MLCK)在包括炎症性疾病、癌症等在内的多种疾病中是一个潜在的治疗靶点。近年来,人们对探索 MLCK 生物学的兴趣大大增加。然而,目前只有一种广泛使用的 MLCK 调节剂,即 ML-7,而且其工作浓度窗口狭窄,毒性高,导致了解有限。在此,我们从聚焦的吲哚烷类化合物库的合成和构效关系研究中报告了一种有效的、高选择性的化学探针 Myokinasib-II 的鉴定。值得注意的是,它的结构与 ML-7 不同,因此根据推荐的最佳实践,它满足了研究 MLCK 生物学的替代抑制剂的需求。此外,我们广泛的基准测试研究表明,与其他已知的 MLCK 抑制剂相比,Myokinasib-II 具有更好的效力、更好的选择性谱,并且在相关测定中没有非特异性干扰。